From clinical practice to mechanistic insights in ketogenic diets for epilepsy.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing clinical practice, mechanistic hypotheses, and existing evidence without a systematic review protocol.
PubMed 41831475 · doi:10.1016/S1474-4422(26)00008-6
What was done
This review evaluates ketogenic diet therapies—including the classic ketogenic diet, modified Atkins diet, and low glycaemic index treatment—for epilepsy management, outlining proposed mechanisms of action (metabolic shift, mitochondrial support, neuroinflammation reduction, neurotransmitter modulation, and gut microbiome alterations) and summarizing the current clinical evidence landscape.
What was found
The abstract provides no quantitative effect sizes or numerical trial data. It reports that ketogenic diet therapies are effective for seizure control, with less restrictive variants offering improved tolerability and feasibility. It notes that Cochrane reviews and meta-analyses categorize the certainty of randomized controlled trial evidence as limited, and that early initiation yields better outcomes, especially in pediatric or metabolic epilepsy populations.
Why it matters
It outlines how alternative, less restrictive dietary protocols can broaden access to metabolic therapy in epilepsy while highlighting the mechanistic rationale for initiating therapy early to protect mitochondrial and neuronal function.
Limits
The abstract contains no primary quantitative data, sample size details, or systematic search methodology. The review acknowledges that current randomized evidence for ketogenic diets is constrained by methodological limitations, heterogeneity, and potential performance and observation biases.
Cited by
- supports Ketogenic metabolic therapy has been used clinically in children for decades to manage epilepsy.